Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukaemic cells U937 and the induction of low levels of intracellular superoxide anion

Toxicology and Applied Pharmacology

Volumn 258, Issue 3, 2012, Pages 351-366

  Lombardo, Tomás ^a   Cavaliere, Victoria ^a,b   Costantino, Susana N ^a   Kornblihtt, Laura ^a   Alvarez, Elida M ^a   Blanco, Guillermo A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Arsenite; Flow cytometry; Leukemia; Superoxide anion; Synergism; U937

Indexed keywords

ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAFFEIC ACID PHENYLETHYL ESTER; HYDROGEN PEROXIDE; SUPEROXIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL DEATH; CELL STRAIN U937; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GROWTH INHIBITION; LEUKEMIA CELL; MYELOID LEUKEMIA; RAJI CELL;

ANTINEOPLASTIC AGENTS; ARSENITES; BURKITT LYMPHOMA; CELL DEATH; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; HYDROGEN PEROXIDE; LEUKEMIA, MYELOID, ACUTE; LEUPEPTINS; REACTIVE OXYGEN SPECIES; SODIUM COMPOUNDS; SUPEROXIDES; TIME FACTORS; U937 CELLS;

EID: 84855932099     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.11.018     Document Type: Article

References (46)

1. Carter W.O., Narayanan P.K., Robinson J.P. Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J. Leukoc. Biol. 1994, 55:253-258.
2. Casarett L.J., Doull J., Klaassen C.D. Casarett and Doull's toxicology: The Basic Science of Poisons 2008, McGraw-Hill, New York.
3. Cavaliere V., Papademetrio D.L., Lorenzetti M., Valva P., Preciado M.V., Gargallo P., Larripa I., Monreal M.B., Pardo M.L., Hajos S.E., Blanco G.A., Alvarez E.M. Caffeic acid phenylethyl ester and MG-132 have apoptotic and antiproliferative effects on leukemic cells but not on normal mononuclear cells. Transl. Oncol. 2009, 2:46-58.
4. Cerda Zolezzi P., Fernandez T., Aulicino P., Cavaliere V., Greczanik S., Caldas Lopes E., Wagner M., Ricco R., Gurni A., Hajos S., Alvarez E. Ligaria cuneifolia flavonoid fractions modulate cell growth of normal lymphocytes and tumor cells as well as multidrug resistant cells. Immunobiology 2005, 209:737-749.
5. Chanan-Khan A.A., Borrello I., Lee K.P., Reece D.E. Development of target-specific treatments in multiple myeloma. Br. J. Haematol. 2010, 151:3-15.
6. Chen G.Q., Zhu J., Shi X.G., Ni J.H., Zhong H.J., Si G.Y., Jin X.L., Tang W., Li X.S., Xong S.M., Shen Z.X., Sun G.L., Ma J., Zhang P., Zhang T.D., Gazin C., Naoe T., Chen S.J., Wang Z.Y., Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide As2O3 in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88:1052-1061.
7. Chen Y., Azad M.B., Gibson S.B. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ. 2009, 16:1040-1052.
8. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
9. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
10. Chou W.C., Dang C.V. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr. Opin. Hematol. 2005, 12:1-6.
11. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 2010, 15:243-249.
12. Girgis E., Mahoney J., Darling-Reed S., Soliman M. Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell line. Oncol. Lett. 2010, 1:473-479.
13. Han S.S., Kim K., Hahm E.R., Park C.H., Kimler B.F., Lee S.J., Lee S.H., Kim W.S., Jung C.W., Park K., Kim J., Yoon S.S., Lee J.H., Park S. Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J. Cell. Biochem. 2005, 94:695-707.
14. He Y., Yang J.M., Wang J.M., Zhou H., Lu S.Q., Hu X.X. Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008, 16:794-798.
15. Hedley D.W., Chow S. Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry 1994, 15:349-358.
16. Hu J., Liu Y.F., Wu C.F., Xu F., Shen Z.X., Zhu Y.M., Li J.M., Tang W., Zhao W.L., Wu W., Sun H.P., Chen Q.S., Chen B., Zhou G.B., Zelent A., Waxman S., Wang Z.Y., Chen S.J., Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3342-3347.
17. Izeradjene K., Douglas L., Tillman D.M., Delaney A.B., Houghton J.A. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. 2005, 65:7436-7445.
18. Jin U.H., Song K.H., Motomura M., Suzuki I., Gu Y.H., Kang Y.J., Moon T.C., Kim C.H. Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in human myeloid leukemia U937 cells. Mol. Cell. Biochem. 2008, 310:43-48.
19. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102-2111.
20. Kchour G., Tarhini M., Kooshyar M.M., El Hajj H., Wattel E., Mahmoudi M., Hatoum H., Rahimi H., Maleki M., Rafatpanah H., Rezaee S.A., Yazdi M.T., Shirdel A., de The H., Hermine O., Farid R., Bazarbachi A. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532.
21. Li L., Wang J., Ye R.D., Shi G., Jin H., Tang X., Yi J. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J. Cell. Physiol. 2008, 217:486-493.
22. Li Z.W., Chen H., Campbell R.A., Bonavida B., Berenson J.R. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr. Opin. Hematol. 2008, 15:391-399.
23. Lu D., Bai X.C., Gui L., Su Y.C., Deng F., Liu B., Li X.M., Zeng W.S., Cheng B.L., Luo S.Q. Hydrogen peroxide in the Burkitt's lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway. Br. J. Haematol. 2004, 125:512-520.
24. Markovic J., Borras C., Ortega A., Sastre J., Vina J., Pallardo F.V. Glutathione is recruited into the nucleus in early phases of cell proliferation. J. Biol. Chem. 2007, 282:20416-20424.
25. McCollum G., Keng P.C., States J.C., McCabe M.J. Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells. J. Pharmacol. Exp. Ther. 2005, 313:877-887.
26. Momeny M., Zakidizaji M., Ghasemi R., Dehpour A.R., Rahimi-Balaei M., Abdolazimi Y., Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med. Oncol. 2010, 27:833-842.
27. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 2008, 9:1157-1165.
28. Ortiz-Lazareno P.C., Hernandez-Flores G., Dominguez-Rodriguez J.R., Lerma-Diaz J.M., Jave-Suarez L.F., Aguilar-Lemarroy A., Gomez-Contreras P.C., Scott-Algara D., Bravo-Cuellar A. MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-kappaB and activator protein-1. Immunology 2008, 124:534-541.
29. Peng C.Y., Jiang J., Zheng H.T., Liu X.S. Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines. Leuk. Lymphoma 2010, 51:297-303.
30. Ramos A.M., Aller P. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines. Biochem. Pharmacol. 2008, 75:1912-1923.
31. Ramos A.M., Fernandez C., Amran D., Esteban D., de Blas E., Palacios M.A., Aller P. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. J. Cell. Physiol. 2006, 209:1006-1015.
32. Ramos A.M., Fernandez C., Amran D., Sancho P., de Blas E., Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 2005, 105:4013-4020.
33. Ravandi F., Estey E., Jones D., Faderl S., O'Brien S., Fiorentino J., Pierce S., Blamble D., Estrov Z., Wierda W., Ferrajoli A., Verstovsek S., Garcia-Manero G., Cortes J., Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol. 2009, 27:504-510.
34. Roboz G.J., Ritchie E.K., Curcio T., Provenzano J., Carlin R., Samuel M., Wittenberg B., Mazumdar M., Christos P.J., Mathew S., Allen-Bard S., Feldman E.J. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008, 113:2504-2511.
35. Roccaro A.M., Vacca A., Ribatti D. Bortezomib in the treatment of cancer. Recent Pat. Anticancer Drug Discov. 2006, 1:397-403.
36. Sanchez Y., Simon G.P., Calvino E., de Blas E., Aller P. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. J. Pharmacol. Exp. Ther. 2010, 335:114-123.
37. Sarkar A., Mandal G., Singh N., Sundar S., Chatterjee M. Flow cytometric determination of intracellular non-protein thiols in Leishmania promastigotes using 5-chloromethyl fluorescein diacetate. Exp. Parasitol. 2009, 122:299-305.
38. Sekeres M.A., Maciejewski J.P., Erba H.P., Afable M., Englehaupt R., Sobecks R., Advani A., Seel S., Chan J., Kalaycio M.E. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 2011, 117:1253-1261.
39. Sumi D., Shinkai Y., Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol. Appl. Pharmacol. 2010, 244:385-392.
40. Sun Q.X., Meng F.Y., Fu Y.B., Li L., Tian S. HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:1022-1025.
41. Tabellini G., Cappellini A., Tazzari P.L., Fala F., Billi A.M., Manzoli L., Cocco L., Martelli A.M. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J. Cell. Physiol. 2005, 202:623-634.
42. Takahashi S. Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem. 2010, 10:504-510.
43. Tallarida R.J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 2001, 298:865-872.
44. Wang Z.G., Rivi R., Delva L., Konig A., Scheinberg D.A., Gambacorti-Passerini C., Gabrilove J.L., Warrell R.P., Pandolfi P.P. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998, 92:1497-1504.
45. Yan H., Wang Y.C., Li D., Wang Y., Liu W., Wu Y.L., Chen G.Q. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia 2007, 21:1488-1495.
46. Zanotto-Filho A., Delgado-Canedo A., Schroder R., Becker M., Klamt F., Moreira J.C. The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett. 2010, 288:192-203.